Home Equities Score Reasons why investors should trust Edesa Biotech Inc. (EDSA) for the long-term

Reasons why investors should trust Edesa Biotech Inc. (EDSA) for the long-term

Edesa Biotech, Inc. (NASDAQ: EDSA) shares were trending lower in the pre-market as it seems to give back some of its gains from last night’s close. A total of +46.95% has been achieved by the EDSA stock over the past five days, from $5.01 to $9.10. In the past month of trading, this stock has moved from $4.05 to $9.10, a change of +56.16%. For the past three months, this stock’s price changed by +18.17%, trading in the range of $4.05 to $9.10.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.  

What they do…


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


Edesa Biotech, Inc. is focused on developing innovative treatments for inflammatory and immune-related illnesses with significant unmet medical needs. Both EB05 and EB01, the company’s leading product candidates, are in late-stage clinical trials.

Read More

What happened…

The company has received FDA / Health Canada approval to add to the ongoing Phase 2/ Phase 3 clinical study of Edesa Biotech (NASDAQ: EDSA) to treat Acute Respiratory Distress Syndrome (ARDS), the leading cause of death in COVID-19 patients. In this substudy, the drug will be examined as potential COVID-19 rescue therapy.

Chief Executive Officer of Edesa, Dr. Par Nijhawan, told physicians involved in the company’s ARDS study that the company identified a group of COVID-19 patients who could benefit from the experimental treatment but weren’t well enough for the main study. Dr. Nijhawan said this sub-study expands the ability to treat critically ill patients suffering from profound, medically refractory COVID 19 respiratory failure.

One sub-study of Edesa is expected to enroll up to 100 in-hospital patients with severe COVID-19 symptoms, including patients receiving extracorporeal membrane oxygenation (ECMO) therapy or being ventilated for more than five days. The sub-study is not expected to affect the design or results of Edesa’s ongoing international Phase 2/3 study.

The Vice President of Research and Development at Edesa, Blair Gordon, PhD., stated that all data would be aggregated and metered together. There will be separate analyses of the sub-study and the main study, which are identical except for the patient enrollment criteria. The study design’s efficiency enables us to efficiently assess the utility of the EB05 across a broad range of hospitalized patients.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.  

Summary

FactSet Research has revealed that one brokerage house has rated the stock as a buy. No analysts have rated it as a sell or overweight. One analyst has given it a buy recommendation. Meanwhile, the consensus is a buy rating.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Apple Inc. (AAPL) Stocks dip but future prospects for the company seem very positive

On Thursday, Apple shares (NASDAQ: AAPL) closed at $120.99 which is 3.5% lower. In the after-hours session, the price further declined by 0.2%.  The...

Tesla Inc. (TSLA): a Game of Thrones, Tweets and Bitcoin

Tesla Inc. (NASDAQ: TSLA) shares plunged by more than 8% when the market closed on Thursday. The news that most significantly impacted this plunge...

The Reasons Behind 30% Fall Of Tricida, Inc.’s (TCDA) Shares In Extended Trades

The drugmaker Tricida, Inc.’s (TCDA) shares experienced a fall of -29.62% in the trading after the ring of the bell on Thursday. The South...

Why Chromadex Corp. (CDXC) Remains A Gainer After Ring Of The Bell?

The biotechnology company ChromaDex Corporation (CDXC) continued the rally after ring of the bell on Thursday rising +18.68%. During the regular session price of...

ReTo Eco-Solutions Stock Drops Pre-Market Today: Why?

The manufacturer and distributor of construction material ReTo Eco-Solutions Inc. (NASDAQ: RETO) has been experiencing a fall of more than 10% in pre-market session...

Were You Wondering Why Northern Dynasty (NAK) Stock Spiked 24% In Early Trades Today?

Shares of mineral exploration firm Northern Dynasty Minerals Ltd. (NYSE: NAK) has been gaining momentum in early trades today. As of 11:42 a.m. EST,...

What Took Gabelli Healthcare (GRX) Stock Down 18% In Pre-Market?

The Gabelli Healthcare & Wellness Trust (GRX) is sinking -18.33% in pre-market trading today following the announcement of a cash distribution by the organization...

What’s Hurting Tengasco Inc (TGC) Stock? Why Is It Down 26% Pre-Market?

Stock of oil and gas exploration firm Tengasco, Inc. (NYSE: TGC) is seeing a decline in pre-market trades today. Shares of the company were...

Related News

Why Atlas Crest Investment (ACIC) Stock Has Risen 9% After-Hour On Friday?

Atlas Crest Investment Corporation (NYSE: ACIC) stock came rising +8.91 to $12.96 in after-hour trading on Friday. The company saw its price falling -2.14%...

Were You Wondering Why Northern Dynasty (NAK) Stock Spiked 24% In Early Trades Today?

Shares of mineral exploration firm Northern Dynasty Minerals Ltd. (NYSE: NAK) has been gaining momentum in early trades today. As of 11:42 a.m. EST,...

What’s Hurting Tengasco Inc (TGC) Stock? Why Is It Down 26% Pre-Market?

Stock of oil and gas exploration firm Tengasco, Inc. (NYSE: TGC) is seeing a decline in pre-market trades today. Shares of the company were...

Why did Armstrong Flooring, Inc. (AFI) stock gain traction after-hours?

After remaining stable during the regular session, shares of Armstrong Flooring, Inc. (NYSE: AFI) get traction in after-hours trading on Thursday on a definitive...

Why Pandion Therapeutics [PAND] Stock Skyrocketing Pre-Market Today?

Pandion Therapeutics Inc. (NASDAQ: PAND) stock has been skyrocketing in pre-market trades today following news of a definitive agreement of acquisition. As of 08:50...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Insider Watchlist

Important Earnings

We do not sell or share your information with anyone.